📣 VC round data is live. Check it out!

Senzime Valuation Multiples

Discover Senzime's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Medicalgorithmics, Episurf Medical, Nexstim, FluoGuide and more.

Senzime Overview

About Senzime

Senzime AB is a medical device company providing patient monitoring systems. Its portfolio comprises systems for patient monitoring of neuromuscular function and breathing, typically during and after surgery, and for the intensive care sector. TetraGraph is a system based on EMG technology for neuromuscular monitoring during surgical procedures. ExSpiron 2Xi is a non-invasive monitoring system of respiratory volume and minute ventilation used for in and out patient care. The company operates in Sweden, Germany and the USA. It derives revenue through sales of monitors and associated disposable sensors to hospitals and clinics.


Founded

1999

HQ

Sweden

Employees

54

Financials (LTM)

Revenue: $14M
EBITDA: ($8M)

EV

$69M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Senzime Financials

Senzime reported last 12-month revenue of $14M and negative EBITDA of ($8M).

In the same LTM period, Senzime generated $6M in gross profit, ($8M) in EBITDA losses, and had net loss of ($12M).

Revenue (LTM)


Senzime P&L

In the most recent fiscal year, Senzime reported revenue of $12M and EBITDA of ($11M).

Senzime is unprofitable as of last fiscal year, with gross margin of 32%, EBITDA margin of (95%), and net margin of (128%).

See analyst estimates for Senzime
LTMLast FY202320242025202620272028
Revenue$14M$12M$4M$6M$11M
Gross Profit$6M$4M$896K$2M$4M
Gross Margin42%32%23%34%33%
EBITDA($8M)($11M)($12M)($10M)($12M)
EBITDA Margin(61%)(95%)(324%)(163%)(110%)
EBIT Margin(81%)(111%)(374%)(224%)(115%)
Net Profit($12M)($15M)($14M)($13M)($15M)
Net Margin(87%)(128%)(375%)(203%)(132%)

Financial data powered by Morningstar, Inc.

Senzime Stock Performance

Senzime has current market cap of $75M, and enterprise value of $69M.

Market Cap Evolution


Senzime's stock price is $0.48.

Senzime share price decreased by 11.9% in the last 30 days, and by 14.9% in the last year.

Senzime has an EPS (earnings per share) of $-0.09.

See more trading valuation data for Senzime
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$69M$75M-4.2%-11.9%4.1%-14.9%$-0.09

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Senzime Valuation Multiples

Senzime trades at 5.0x EV/Revenue multiple, and (8.2x) EV/EBITDA.

See NTM and 2027E valuation multiples for Senzime

EV / Revenue (LTM)


Senzime Financial Valuation Multiples

As of June 3, 2026, Senzime has market cap of $75M and EV of $69M.

Senzime has a P/E ratio of (6.4x).

LTMLast FY202320242025202620272028
EV/Revenue5.0x5.9x17.8x10.9x6.1x
EV/EBITDA(8.2x)(6.2x)(5.5x)(6.7x)(5.6x)
EV/EBIT(6.2x)(5.3x)(4.8x)(4.9x)(5.3x)
EV/Gross Profit12.1x18.4x76.5x31.7x18.4x
P/E(6.4x)(5.1x)(5.2x)(5.9x)(5.1x)
EV/FCF-(5.0x)(5.2x)(5.1x)(5.0x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Senzime Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Senzime Margins & Growth Rates

Senzime grew revenue by 42% but EBITDA decreased by 57% in the last fiscal year.

In the most recent fiscal year, Senzime reported gross margin of 32%, EBITDA margin of (95%), and net margin of (128%).

See estimated margins and future growth rates for Senzime

Senzime Margins

Last FY202420252026202720282029
Gross Margin32%34%33%50%
EBITDA Margin(95%)(163%)(110%)(29%)
EBIT Margin(111%)(224%)(115%)(45%)
Net Margin(128%)(203%)(132%)(43%)
FCF Margin(118%)(216%)(122%)-

Senzime Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth42%64%78%47%
Gross Profit Growth120%141%72%120%
EBITDA Growth(57%)(18%)20%(62%)
EBIT Growth(43%)(2%)(9%)(43%)
Net Profit Growth(52%)(11%)16%(52%)
FCF Growth-4%1%-

Data powered by FactSet, Inc. and Morningstar, Inc.

Senzime Operational KPIs

Senzime's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.3M for the same period.

Senzime's Rule of 40 is 18% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Senzime's Rule of X is 89% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Senzime
LTMLast FY202320242025202620272028
Rule of 40(14%)18%---
Bessemer Rule of X56%89%---
Revenue per Employee-$0.2M---
Opex per Employee-$0.3M---
S&M Expenses to Revenue75%94%217%158%94%
G&A Expenses to Revenue28%33%126%65%33%
R&D Expenses to Revenue19%22%54%38%22%
Opex to Revenue-144%397%259%149%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Senzime Competitors

Senzime competitors include Medicalgorithmics, Episurf Medical, Nexstim, FluoGuide, Research Solutions, Vuno, electroCore, BlinkLab, Champions Oncology and Applied BioCode.

Most Senzime public comparables operate across Medical Devices, Health Data & Analytics, HealthTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Medicalgorithmics12.3x7.7x(24.7x)231.8x
Episurf Medical52.0x-(14.2x)-
Nexstim5.9x5.5x35.3x31.7x
FluoGuide--(11.5x)(10.5x)
Research Solutions1.2x1.3x11.5x10.2x
Vuno2.5x-(23.9x)-
electroCore2.5x2.2x(9.1x)(10.5x)
BlinkLab-3715.8x--

This data is available for Pro users. Sign up to see all Senzime competitors and their valuation data.

Start Free Trial

Senzime VC Funding History

Before going public, Senzime raised $300K in total equity funding, across 1 round.


Senzime Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Apr-17Pre-seed-$300K--

Acquisitions by Senzime

Senzime has acquired 3 companies to date.

Last acquisition by Senzime was on June 1st 2022. Senzime acquired Respiratory Motion for $19M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Senzime

Respiratory Motion
Acacia Designs
MD Biomedical
Description
Respiratory Motion is a Burlington, Massachusetts-headquartered commercial-stage medtech company specializing in respiratory monitoring devices. Its PEEP technology assesses diaphragm function across diverse patient populations in ICUs, ORs, and wards, providing early warnings of respiratory failure. FDA-cleared products support clinical evaluations and manufacturing for global distribution in critical care environments.
Acacia Designs is a Dutch medical device company headquartered in the Netherlands that develops electromyography-based neuromuscular monitoring systems. Its flagship TetraGraph System provides real-time quantitative monitoring of neuromuscular blockade during anesthesia, reducing postoperative residual paralysis risks. The battery-operated device integrates with anesthesia machines and features advanced signal processing for precise train-of-four assessments. Sold in Europe and beyond, Acacia's solutions comply with EU MDR standards and serve hospitals performing over 500,000 surgeries yearly equipped with the technology.
MD Biomedical AB is a Lund-based medical device company developing Onzurf, a microdialysis catheter for postoperative organ monitoring in Europe. The product tracks lactate, glucose, and glycerol levels in bowel, liver, and heart tissues to detect ischemia and anastomotic leaks early, used in surgical units at Uppsala University Hospital and other Scandinavian centers.
HQ CountryUnited StatesNetherlandsSweden
HQ City
Boston, MA
Maastricht
Umeå
Deal Date1 Jun 20223 May 201624 Apr 2015
Valuation$19M$18Mundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Senzime acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Senzime

When was Senzime founded?Senzime was founded in 1999.
Where is Senzime headquartered?Senzime is headquartered in Sweden.
How many employees does Senzime have?As of today, Senzime has over 54 employees.
Who is the CEO of Senzime?Senzime's CEO is Philip Siberg.
Is Senzime publicly listed?Yes, Senzime is a public company listed on Nasdaq Stockholm.
What is the stock symbol of Senzime?Senzime trades under SEZI ticker.
When did Senzime go public?Senzime went public in 2008.
Who are competitors of Senzime?Senzime main competitors include Medicalgorithmics, Episurf Medical, Nexstim, FluoGuide, Research Solutions, Vuno, electroCore, BlinkLab, Champions Oncology, Applied BioCode.
What is the current market cap of Senzime?Senzime's current market cap is $75M.
What is the current revenue of Senzime?Senzime's last 12 months revenue is $14M.
What is the current revenue growth of Senzime?Senzime revenue growth (NTM/LTM) is 47%.
What is the current EV/Revenue multiple of Senzime?Current revenue multiple of Senzime is 5.0x.
Is Senzime profitable?No, Senzime is not profitable.
What is the current EBITDA of Senzime?Senzime has negative EBITDA and is not profitable.
What is Senzime's EBITDA margin?Senzime's last 12 months EBITDA margin is (61%).
What is the current EV/EBITDA multiple of Senzime?Current EBITDA multiple of Senzime is (8.2x).
How many companies Senzime has acquired to date?As of June 2026, Senzime has acquired 3 companies.
What was the largest acquisition by Senzime?$19M acquisition of Respiratory Motion on 1st June 2022 was the largest M&A Senzime has done to date.
What companies Senzime acquired?Senzime acquired Respiratory Motion, Acacia Designs, and MD Biomedical.
In how many companies Senzime has invested to date?Senzime hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Senzime

Lists including Senzime

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial